Mutations and Metabolic Factors Affecting Interaction of Toxigenic and Atoxigenic Aspergillus flavus
Szilvia Kovács1, Barbara Brendzsák1, Walter P Pfliegler2
1Central Laboratory of Agricultural and Food Products, Faculty of Agricultural and Food Sciences and Environmental Management, University of Debrecen, Böszörményi Str. 138, H-4032 Debrecen, Hungary.
Abstract:
Aflatoxin B1 (AFB1) produced by Aspergillus flavus poses severe food safety risks. Competitive exclusion using atoxigenic A. flavus strains offers a promising biological control approach to managing agricultural contamination by reducing populations of toxigenic strains and aflatoxin levels. However, reliable identification of atoxigenic strains remains challenging, and the mechanisms underlying competitive interactions between toxigenic and atoxigenic strains require clarification for effective implementation. Therefore, this study systematically analysed A. flavus strains for aflatoxin gene clusters and AFB1 production to address these critical gaps. Our analysis revealed that atoxigenic strains had intron losses and high-impact mutations in several genes, particularly aflL and aflLa, which affect aflatoxin biosynthesis. Key genes norA/aflE, verA/aflN, and omtA/aflP emerged as mutation hotspots, sometimes causing false-negative PCR results that complicate strain identification. Also, AFB1 production was inversely related to spore concentration on MEA medium, with fewer spores resulting in higher toxin levels. Interaction tests demonstrated that toxigenic and atoxigenic strains exhibited morphological changes only when co-cultured without physical separation, suggesting that this was mediated by diffusible molecules. Furthermore, differences in the levels of linoleic acid reduction products distinguished toxigenic from atoxigenic strains. These findings thus illuminate the complex genetic and metabolic factors influencing aflatoxin production and fungal interactions.
Related Concept Videos
Fungal Phylum Ascomycota
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Drug toxicity: Idiosyncratic Reactions
Drug Toxicity: Risk factors
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Mutagenicity and Carcinogenicity


